LPAR1 and myeloid sarcoma: Moreover, LPA1 expression is associated with a pro-inflammatory phenotype of macrophages and contributes to the development of MS and experimental autoimmune encephalomyelitis (EAE) (Figure 2), indicating LPA1 as a therapeutic target biomarker for MS and EAE [60].